. Author manuscript; available in PMC: 2015 Sep 1.

Published in final edited form as: Cancer Res. 2014 Jun 26;74(17):4822–4835. doi: 10.1158/0008-5472.CAN-14-0584

Table 2.

CIs of dual-drug combinations in different breast cancer cells.

Drug combination	CI

	ED₅₀	ED₇₅	ED₉₀	ED₉₅

MDA-MB-231
Sa-Cr	1.00	0.66	0.44	0.35
Sa-PD	1.03	0.70	0.57	0.57
Cr-PD	0.39	0.76	1.72	3.27
BT549
Sa-Cr	1.96	0.68	0.27	0.15
Sa-PD	0.81	0.74	0.70	0.69
Cr-PD	1.11	1.02	0.94	0.89
Hs578T
Sa-Cr	0.52	0.60	0.71	0.79
Sa-PD	0.58	0.79	1.17	1.56
Cr-PD	0.53	1.26	3.20	6.05
SK-BR-3
Sa-Cr	1.23	1.07	0.93	0.84
Sa-PD	1.20	1.25	1.30	1.34
Cr-PD	1.55	1.45	1.36	1.31
T47D
Sa-Cr	0.99	0.90	0.85	0.82
Sa-PD	1.04	0.99	1.06	1.15
Cr-PD	1.11	1.18	1.26	1.32
MCF10A
Sa-Cr	3.03	13.10	59.89	168.96
Sa-PD	1.42	1.20	1.04	0.96
Cr-PD	1.22	1.09	1.01	0.98

Note: TNBC cells (MDA-MB-231, BT549, and Hs578T), non-TNBC cells (T47D and SK-BR-3), and normal epithelial cells (MCF10A) were used to determine the CI index of safingol (SA), crizotinib (Cr), and PD0332991 (PD) in dual-drug combinations. CIs of <1, 1, and >1 indicate synergism, additive effect, and antagonism, respectively. ED, effective dose. CI index <0.9 was labeled as bold text.